What Is Zofenopril?
For the treatment of mild to moderate essential hypertension, and for patients with or without symptoms within 24 hours of acute myocardial infarction, stable hemodynamics and not receiving thrombolytic therapy.
Zofenpril
- This entry lacks an overview map . Supplementing related content makes the entry more complete and can be upgraded quickly. Come on!
- Drug Name
- Zofenpril
- Alias
- Zopranol
- Foreign name
- zofenopril
- Adverse reactions
- Dizziness (3.9%), fatigue (2.6%), headache
- Athletes use with caution
- Use with caution
- For the treatment of mild to moderate essential hypertension, and for patients with or without symptoms within 24 hours of acute myocardial infarction, stable hemodynamics and not receiving thrombolytic therapy.
- Zofenopril
- 1 Product name
- Bifril, Zofenil, Zopranol
- 2 Chemical name
- [1 (R *), 2, 4] -1- [3- (benzoylmercapto) -2-methyl-1-oxopropyl] -4- (phenylthio) -L-proline
- 3.English name
- zofenopril
- 4.CAS number 81872-10-8
- 5. Development and listing vendors
- Developed by Enarini (Italy). Listed in Italy and other countries for the first time on January 8, 2001.
- Pharmacology
- This product is the first long-acting ACE inhibitor containing a thiol group. Because this product contains a thiol group, it has lipophilic and antioxidant properties. This product can be hydrolyzed to the active substance Zofenprilat.
- This product is quickly and completely absorbed after oral administration, and is almost completely converted to Zofenpril. 1.5 hours after administration, the concentration of Zofenpril in the blood reaches a peak. Pharmacokinetics of a single dose of 10-80mg Linear. No drug accumulation was seen in 15-60 mg for 3 weeks. The presence of food in the gastrointestinal tract can affect the rate of drug absorption but not the extent of absorption. Zofenprila's AUC remained almost unchanged.
- Research on the distribution of this product shows that about 88% of this product is related to the body
- Clinical evaluation
- A clinical study involving 1500 patients showed that this product is superior to other ACE inhibitors for primary hypertension and acute myocardial infarction.
- The SMILE-LL clinical study evaluated the tolerability and effectiveness of this product with lisinopril in 1024 patients with acute myocardial infarction who did not receive thrombolytic therapy. The study lasted 6 weeks. As a result, the incidence of severe hypotension was similar between the two groups (10.9% vs. 11.7%). For patients with myocardial infarction, administration within 24 hours of onset of symptoms reduces the risk of severe congestive heart failure and death, a 34% reduction compared to placebo. The 12-month SMILE study showed a 29% reduction in the risk of death.
- Four studies evaluated the tolerability and efficacy of this product in the treatment of primary hypertension. Three efficacy control studies aimed at reducing diastolic blood pressure show the efficacy of this product 30-60mg a day with atenolol 50-100mg a day, amlodipine 5-10mg a day and enalapril 20-40mg quite. The reported adverse melon related to this product are some mild and transient reactions, and rarely withdraw due to adverse reactions.
- Adverse reactions
- The common adverse reactions of this product are dizziness (3.9%), fatigue (2.6%), headache (2.4%), cough (1.2%), nausea or vomiting (1.2%).
- Uncommon adverse melons were flushing (0.8%), muscle spasms (0.8%), and weakness (0.5%).
- Other adverse reactions related to ACE inhibitor treatment: severe hypotension in the cardiovascular system, rare peripheral angioedema, orthostatic hypotension, and chest pain. Myalgia and muscle spasms of the skeletal muscle system. Renal insufficiency and acute renal failure in the renal system. Respiratory cough, dyspnea, sinusitis, rhinitis, glossitis, bronchitis and bronchospasm. Individual patients have fatal respiratory obstruction due to upper respiratory edema. Gastrointestinal tract can be seen vomiting, abdominal pain, diarrhea, constipation and dry mouth.
- Precautions
- The following patients are prohibited from using this product: patients who are allergic to this product or other ACE inhibitors, patients with a history of angioedema related to ACE inhibitor treatment, patients with epidemic or idiopathic angioedema, patients with severe liver dysfunction , Pregnant women, lactating women, women of child-bearing age who have not taken effective contraception, women of child-bearing age who have not taken effective contraception, patients with double renal artery stenosis or single kidney and single renal artery stenosis.
- Excessive use of this product can cause severe hypotension, shock, paralysis, bradycardia, dielectric disturbance and renal failure.
- Usage and dosage
- This mouthful can be used before and after meals, as well as during meals. Adjust the dosage in time according to the situation of the patient.
- When used for the treatment of hypertension, the dose increase should be 4 weeks apart. For patients without body fluids and sodium retention, this product can be used 15mg once a day. The dose is adjusted to reach the optimal blood pressure level. The effective dose is usually 30 mg. The maximum daily dose is 60 mg, which can be administered once or in two divided doses. If the effect is not good, other antihypertensive drugs such as diuretics can be added.
- For patients with suspected body fluids or sodium deficiency, the risk of the first dose of hypotension is high. Calibration for sodium and body fluid deficiencies should be calibrated and diuretics should be discontinued for 2-3 days before starting treatment with ACE inhibitors. If the above conditions cannot be met, the starting dose should be 7.5 mg.
- High-risk patients with severe acute hypotension should be hospitalized as closely as possible for close monitoring. To achieve the best effect after the first dose, diuretics can be added or the dose of this product can be increased. This product is also suitable for the treatment of patients with low blood pressure angina pectoris and coronary heart disease caused by angina pectoris and coronary heart disease.
- No dosage adjustment is needed for mild renal insufficiency lice, and the dosage should be halved in patients with moderate to severe renal insufficiency. The starting dose should be 1/4 of those with normal renal function. In elderly patients with impaired renal function, the dose is halved. Patients with mild to moderate hepatic insufficiency halved the starting dose, while patients with severe hepatic insufficiency are disabled. Not recommended for children.
- Acute myocardial infarction lice can be started using this product for 6 weeks within 24 hours of symptoms. The dose is 7.5 mg every twelve hours on the first and second days, and 30 mg every twelve hours for more than five days. If low systolic blood pressure appears within the first 3 days of treatment, the dose should not be increased. If hypotension occurs during treatment, the original tolerated dose can be used. However, if the systolic pressure is less than 90mmHg for two consecutive measurements within a period of more than 1 hour, you should stop using this product.
- Patients with myocardial infarction should be re-evaluated after 6 weeks of treatment. If there are no symptoms of left ventricular function or heart failure, the medication can be stopped. If symptoms persist, oral treatment should be continued for a longer period of time.
- Use with caution for elderly myocardial infarction lice over 75 years old. Not recommended for patients with myocardial infarction with renal or liver dysfunction.
- preparation
- This mouth is a film-coated tablet, the specifications are: 7.5 (including Zofenpril 7.2mg), 15, 30 and 60mg.